NEW YORK, NY / ACCESSWIRE / September 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws.
Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda’s New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL)."
Following this news, Vanda’s stock price fell sharply during intraday trading on September 19, 2024. To obtain additional information, go to:
https://zlk.com/pslra-1/vanda-pharmaceuticals-inc-lawsuit-submission-form?prid=104053&wire=1
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original press release on accesswire.com
COMTEX_457963694/2457/2024-09-20T09:50:30